Literature DB >> 8014506

Risk factors for Clostridium difficile stool cytotoxin b among critically ill patients: role of sucralfate.

G L Jensen1, J E Bross, P P Bourbeau, D W Naumovitz, M Streater, L E Gianferante.   

Abstract

To identify risk factors other than antimicrobial exposure for Clostridium difficile stool cytotoxin b, subjects admitted to critical care units over 18 months and who had stool cytotoxin assays were evaluated. Twenty-two cases (cytotoxin b-positive) were compared with 125 controls (cytotoxin b-negative). Cases and controls were similar with respect to age, sex, therapeutic index severity score, duration of hospitalization before cytotoxin b testing, and antimicrobial exposure. Adjusted odds ratios (OR) revealed white blood cell count of > 12,000 on the day of stool sampling (OR, 4.0; 95% confidence interval [CI], 1.3-12.4) and sucralfate exposure (OR, 0.15; 95% CI, 0.05-0.42) as significant independent positive and negative risk factors, respectively. Sucralfate exposure may decrease risk for C. difficile stool cytotoxin b by interfering with its detection, altering toxin production, or inhibiting colonization by the organism. Additional evaluation is needed to elucidate the mechanisms involved.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8014506     DOI: 10.1093/infdis/170.1.227

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  5 in total

Review 1.  Laboratory diagnosis of Clostridium difficile infection can molecular amplification methods move us out of uncertainty?

Authors:  Fred C Tenover; Ellen Jo Baron; Lance R Peterson; David H Persing
Journal:  J Mol Diagn       Date:  2011-08-18       Impact factor: 5.568

2.  Evaluation of a new enzyme immunoassay for Clostridium difficile toxin A.

Authors:  S O Vargas; D Horensky; A B Onderdonk
Journal:  J Clin Pathol       Date:  1997-12       Impact factor: 3.411

3.  Implementation of a clinical practice guideline for stress ulcer prophylaxis increases appropriateness and decreases cost of care.

Authors:  S Pitimana-aree; D Forrest; G Brown; A Anis; X H Wang; P Dodek
Journal:  Intensive Care Med       Date:  1998-03       Impact factor: 17.440

4.  Risk of Clostridium difficile diarrhoea in critically ill patients treated with erythromycin-based prokinetic therapy for feed intolerance.

Authors:  Nam Q Nguyen; Katrina Ching; Robert J Fraser; Marianne J Chapman; Richard H Holloway
Journal:  Intensive Care Med       Date:  2007-08-15       Impact factor: 17.440

5.  Variants at the MHC Region Associate With Susceptibility to Clostridioides difficile Infection: A Genome-Wide Association Study Using Comprehensive Electronic Health Records.

Authors:  Jiang Li; Yanfei Zhang; Alexandria L Jilg; Donna M Wolk; Harshit S Khara; Amy Kolinovsky; David D K Rolston; Raquel Hontecillas; Josep Bassaganya-Riera; Marc S Williams; Vida Abedi; Ming Ta Michael Lee
Journal:  Front Immunol       Date:  2021-03-25       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.